Healthcare
Galecto, Inc.(DMRA)
Live Price
Offline$21.23
-0.89% today
1Y Change
+518.95%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $1.50B
- Revenue Growth
- 0.0%
- EPS Growth
- -753.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Galecto, Inc. (DMRA) is a Healthcare stock with a market cap of $1.50B and listed on NASDAQ. The stock last traded around $21.23 and up 519.0% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -753.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -753.4%, free cash flow +63.9% with operating margin 0.0% and ROIC -87.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DMRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -753.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +11.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | β | +3.0% | +4.1% | -13.0% |
2026 Mar 18, 2026 | -2216.3% | -9.2% | +18.4% | +27.7% |
Benchmark Edge
DMRA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DMRA
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DMRA Max Drawdown
-72.38%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DMRA and SPY.
Company Overview
Galecto, Inc.
NASDAQ Global Market
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf JΓΆrgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans ThalsgΓ₯rd Schambye in 2011 and is headquartered in Boston, MA.
- Leadership
- Jennifer A. Jarrett
- IPO Date
- Mar 10, 2026
- Employees
- 7
- Street Address
- Building 23
- Mailing
- Boston, MA, 02453
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 281 9020
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 0.1
Growth
- Revenue
- 0.0%
- EPS
- -753.4%
- Free Cash Flow
- +63.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -312.0%
- ROIC
- -87.7%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 12.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.